TheraRadar
← Back
Data updated: Jun 28, 2026

G AND W LABS INC

Generics

G AND W LABS INC is a generic drug manufacturer focused on Immunology, Gastroenterology, Neurology.

1982
Since
12
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Aug 2, 2026 — RP1 (vusolimogene oderparepvec) + nivolumab
22d
Aug 13, 2026 — LNTH
Aug 19, 2026 — Garetosmab

G AND W LABS INC's Key Drugs

G AND W LABS INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

G AND W LABS INC's Recent FDA Approvals

New NDA/BLA approvals for G AND W LABS INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

G AND W LABS INC's Therapeutic Areas

G AND W LABS INC's approved drugs and pipeline span 4 therapeutic areas, led by Immunology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 25%
1 drugs
Gastroenterology 25%
1 drugs
Neurology 25%
1 drugs
Dermatology 25%
1 drugs

G AND W LABS INC's Top Competitors

G AND W LABS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

G AND W LABS INC Pipeline Snapshot

Active clinical trials for G AND W LABS INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling